Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686868 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00686868 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 35 participants.
The verdict
NCT00686868, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This study will examine the safety and tolerability, PK and PD of subcutaneously administered GSK1841157 in patients with RA on stable dose Methotrexate. The study comprises a single dose escalation/de-escalation phase to investigate the minimal efficacious dose based on PD markers with an acceptable safety profile.
Interventions
- OTHER placebo
- DRUG ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-06-13 |
| Est. Completion | 2011-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686868
The ClinicalTrials.gov registry entry for NCT00686868 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00686868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00686868 about?
NCT00686868 is a clinical study titled "Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients". This study will examine the safety and tolerability, PK and PD of subcutaneously administered GSK1841157 in patients with RA on stable dose Methotrexate. The study comprises a single dose escalation/de-escalation phase to investigate the minimal efficacious dose based on PD markers with an acceptabl...
What is the current status of trial NCT00686868?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2008-06-13. Estimated completion is 2011-05-02.
What interventions are being tested in trial NCT00686868?
The interventions under investigation include: placebo (OTHER), ofatumumab (DRUG).
Who is sponsoring clinical trial NCT00686868?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.